Abstract

One of the most common carcinoma occurring in the head and neck is laryngeal cancer. Despite the rapid scientific advances in medicine the prognosis for patients with such type of disease is not satisfying. In the last few years matrix metalloproteinases ‑ MMPs and their tissue inhibitors – TIMPs, mostly MMP‑2 and MMP‑9, arouses a great interest, especially in the process of carcinogenesis. It seems that their impact in the formation and development of laryngeal cancer is significant. MMPs a group of zinc‑ and calcium‑ dependent endopeptidases play crucial role extracellular matrix collagen degradation. That are enzymes, that degrade and the basement membrane by facilitating tumor growth, cell migration and tumor invasion. They are implicated in metastasis and angiogenesis potentiate within the tumor. Clear tendency was observed towards the higher MMPs and TIMPs expression in larynx cancer than in the stroma. Recent studies show correlations between increased MMP‑2 gene expression in the tumor tissue and clinical status, histopathological grading and metastases occurrence. The similar MMP2 over expression dependence were found on tumor recurrence and survival. Many authors pointed out, significant higher MMP‑2 expression as a potential marker of tumor invasiveness and worse prognosis in patients with larynx cancer. However, association of MMP 9 gene expression with laryngeal cancer clinicopathological features and survival of patients are ambiguous. Although, numerous researches show that this relationship does exists. Similar correlations could be found in TIMPs, but further studies are necessary because of small amount of literature.

References

• 1. Bachmeier B.E., Iancu C.M., Jochum M., Nerlich A.G.: Matrix metalloproteinasesin cancer: comparison of known and novel aspectsof their inhibition as a therapeutic approach. Expert Rev. AnticancerTher., 2005; 5: 149‑163
  Google Scholar
• 2. Baker E.A., Bergin F.G., Leaper D.J.: Matrix metalloproteinases,their tissue inhibitors and colorectal cancer staging. Br. J. Surg.,2000; 87: 1215‑1221
  Google Scholar
• 3. Bień S.: Epidemiologia i klasyfikacja raka krtani. Pol. Merk. Lek.,2005; 19: 464‑466
  Google Scholar
• 4. Christopoulos T.A., Papageorgakopoulou N., Ravazoula P., MastronikolisN.S., Papadas T.A., Theocharis D.A., Vynios D.H.: Expressionof metalloproteinases and their tissue inhibitors in squamous celllaryngeal carcinoma. Oncol. Rep., 2007; 18: 855‑860
  Google Scholar
• 5. Colović Z., Pesutić‑Pisac V., Poljak N.K., Racić G., Cikojević D,Kontić M.: Expression of matrix metalloproteinase‑9 in patientswith squamous cell carcinoma of the larynx. Coll. Antropol., 2013;37: 151‑155
  Google Scholar
• 6. Danilewicz M., Sikorska B., Wagrowska‑Danilewicz M.: Prognostic significance of the immunoexpression of matrix metalloproteinaseMMP2 and its inhibitor TIMP2 in laryngeal cancer. Med. Sci. Monit.,2003; 9: MT42‑MT47
  Google Scholar
• 7. Duan S., Guo Y.: Expression and clinical significance of stromelysin‑3in laryngeal cancer. Lin Chung Er Bi Yan Hou Tou Jing WaiKe Za Zhi, 2008; 22: 104‑107
  Google Scholar
• 8. Duffy M.J.: The role of proteolytic enzymes in cancer invasionand metastasis. Clin. Exp. Metastasis, 1992; 10: 145‑155
  Google Scholar
• 9. Dziankowska‑Bartkowiak B., Waszczykowska E., Żebrowska A.:Udział metaloproteinaz i ich inhibitorów w patomechanizmie wybranychchorób skóry. Alergia Astma Immunol., 2004; 9: 71‑79
  Google Scholar
• 10. Fini M.E., Parks W.C., Rinehart W.B., Girard M.T., MatsubaraM., Cook J.R., West‑Mays J.A., Sadow P.M., Burgeson R.E., JeffreyJ.J., Raizman M.B., Krueger R.R., Zieske J.D.: Role of matrix metalloproteinasesin failure to re‑epithelialize after corneal injury. Am. J.Pathol. 1996; 149: 1287‑1302
  Google Scholar
• 11. Gacko M.: Metaloproteinazy macierzy międzykomórkowej(MMPs). Postępy Hig. Med. Dośw., 1997; 51: 577‑589
  Google Scholar
• 12. Görögh T., Beier U.H., Bäumken J., Meyer J.E., Hoffmann M.,Gottschlich S., Maune S.: Metalloproteinases and their inhibitors:influence on tumor invasiveness and metastasis formation in headand neck squamous cell carcinomas. Head Neck, 2006; 28: 31‑39
  Google Scholar
• 13. Groblewska M., Tycińska A., Mroczko B., Musiał W., SzmitkowskiM.: Metaloproteinazy macierzy zewnątrzkomórkowej w chorobachukładu krążenia. Pol. Merkur. Lekarski, 2011; 30: 235‑240
  Google Scholar
• 14. Gross J., Lapiere C.M.: Collagenolytic activity in amphibian tissues:a tissue culture assay. Proc. Natl. Acad. Sci. USA, 1962; 48: 1014‑1022
  Google Scholar
• 15. Hashibe M., Boffetta P., Zaridze D., Shangina O., Szeszenia‑DabrowskaN., Mates D., Fabiánová E., Rudnai P., Brennan P.: Contributionof tobacco and alcohol to the high rates of squamous cellcarcinoma of the supraglottis and glottis in Central Europe. Am. J.Epidemiol., 2007; 165: 814‑820
  Google Scholar
• 16. Iqbal A., Warraich R., Udeabor S.E., Rana M., Eckardt A.M., GellrichN.C., Rana M.: Role of human papillomavirus infection and otherfactors in patients with head and neck squamous cell carcinoma.Oral Dis., 2014; 20: 288‑293
  Google Scholar
• 17. Itoh T., Matsuda H., Tanioka M., Kuwabara K., Itohara S., Suzuki R.:The role of matrix metalloproteinase‑2 and matrix metalloproteinase‑9in antibody‑induced arthritis. J. Immunol., 2002; 169: 2643‑2647
  Google Scholar
• 18. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., ItoharaS.: Reduced angiogenesis and tumour progression in a gelatinaseA‑deficient mice. Cancer Res., 1998; 58: 1048‑1051
  Google Scholar
• 19. Jassem J., Kawecki A., Krajewski R., Krzakowski M.: Nowotworynabłonkowe narządów głowy i szyi. Zalecenia diagnostyczno‑terapeutycznePolskiej Unii Onkologii. Nowotwory, 2003; 53: 552‑569
  Google Scholar
• 20. Józefowicz‑Korczyńska M., MazerantM., Morshed K., OlejniczakI., Bojanowska‑Poźniak K.: Wstępna ocena zależności pomiędzy zakażeniemHPV a wybranymi cechami nowotworu u chorych na rakakrtani. Otorynolaryngologia – przegląd kliniczny. 2014; 13: 155‑162
  Google Scholar
• 21. Jurkiewicz D., Dżaman K., Rapiejko P.: Czynniki ryzyka raka krtani.Pol. Merkur. Lekarski, 2006; 21: 94‑98
  Google Scholar
• 22. Kapral M., Strzałka‑Mrozik B., Paluch J., Kowalczyk M., JurzakM., Weglarz L.: Evaluation of gene expression of selected matrixmetalloproteinases and their tissue inhibitors in laryngeal cancer.Farm. Przegl. Nauk., 2010; 10: 41‑46
  Google Scholar
• 23. Kim J.M., Kim H.J., Koo B.S., Rha K.S., Yoon Y.H.: Expression ofmatrix metalloproteinase‑12 is correlated with extracapsular spreadof tumor from nodes with metastasis in head and neck squamouscell carcinoma. Eur. Arch. Otorhinolaryngol., 2013; 270: 1137‑1142
  Google Scholar
• 24. Kotulska‑Wolwender K., Larysz‑Brysz M., Fus Z., KorczyńskaI., Górka D., Lewin‑Kowalik J.: Metaloproteinazy macierzy pozakomórkowej‑perspektywy ich wykorzystania w medycynie. Wiad.Lek., 2002; 55: 463‑471
  Google Scholar
• 25. Krajowy Rejestr Nowotworów 2010; http://onkologia.org.pl/
  Google Scholar
• 26. Kręcicki T., Fraczek M., Jelen M., Podhorska M., SzkudlarekT., Zatonski T.: Expression of collagenase‑1 (MMP‑1), collagenase‑3(MMP‑13) and tissue inhibitor of matrix metalloproteinase‑1(TIMP‑1) in laryngeal squamous cell carcinomas. Eur. Arch. Otorhinolaryngol.,2003; 260: 494‑497
  Google Scholar
• 27. Kręcicki T., Zalesska‑Krecicka M., Jelen M., Szkudlarek T., HorobiowskaM.: Expression of type IV collagen and matrix metalloproteinase‑2(type IV collagenase) in relation to nodal status in laryngealcancer. Clin. Otolarygol. Allied Sci., 2001; 26: 469‑472
  Google Scholar
• 28. Kubben F.J., Sier C.F., van Duijn W., Griffioen G., Hanemaaijer R.,van de Velde C.J., van Krieken J.H., Lamers C.B., Verspaget H.W.: Matrixmetalloproteinase‑2 is a consistent prognostic factor in gastriccancer. Br. J. Cancer, 2006; 94: 1035‑1040
  Google Scholar
• 29. Kwiatkowski P., Godlewski J., Śliwińska‑Jewsiewicka A., KmiećZ.: Rola metaloproteinaz macierzy zewnątrzkomórkowej w procesieinwazji nowotworu. Pol. Ann. Med., 2008; 15: 43‑50
  Google Scholar
• 30. Lipka D., Boratyński J.: Metaloproteinazy MMP. Struktura i funkcja.Postępy Hig. Med. Dośw., 2008; 62: 328‑336
  Google Scholar
• 31. Liu R.R., Li M.D., Li T., Tan Y., Zhang M., Chen J.C.: Matrix metalloproteinase 2 (MMP2) protein expression and laryngeal cancerprognosis: a metaanalysis. Int. J. Clin. Exp. Med., 2015; 8: 2261‑2266
  Google Scholar
• 32. Liu W., Xiang C., Jia S.: Study on the expression of matrix metalloproteinase‑12and NM_002426 in squamous laryngeal carcinoma.Lin Chuang Er Bi Yan Hou Ke Za Zhi, 2006; 20: 1120‑1123
  Google Scholar
• 33. Liu W.W., Zeng Z.Y., Wu Q.L, Hou J.H., Chen Y.Y.: Overexpressionof MMP‑2 in laryngeal squamous cell carcinoma: a potentialindicator for poor prognosis. Otolaryngol. Head Neck Surg., 2005;132: 395‑400
  Google Scholar
• 34. Liu Y., Li Y., Liu Z., Zhang L., Anniko M., Duan M.: Prognostic significanceof matrix metalloproteinase‑20 overexpression in laryngealsquamous cell carcinoma. Acta Otolaryngol., 2011; 131: 769‑773
  Google Scholar
• 35. Łapka A., Drąg J., Goździalska A., Jaśkiewicz J.: Metaloproteinazymacierzy pozakomórkowej w glejakach. Postępy Psychiatrii i Neurologii,2008; 17: 207‑211
  Google Scholar
• 36. Machiels J.P., Lambrecht M., Hanin F.X., Duprez T., Gregoire V.,Schmitz S., Hamoir M.: Advances in the management of squamouscell carcinoma of the head and neck. F1000Prime Rep., 2014; 6: 44
  Google Scholar
• 37. Magary S.P., Ryan M.W., Tarnuzzer R.W., Kornberg L.: Expressionof matrix metalloproteinases and tissue inhibitor of metalloproteinasesin laryngeal and pharyngeal squamous cell carcinoma: a quantitativeanalysis. Otolaryngol Head Neck Surg., 2000; 122: 712‑716
  Google Scholar
• 38. Mallis A., Teymoortash A., Mastronikolis N.S., Werner J.A., PapadasT.A.: MMP‑2 expression in 102 patients with glottic laryngealcancer. Eur. Arch. Otorhinolaryngol., 2012; 269: 639‑642
  Google Scholar
• 39. Murray G.I., Duncan M.E., O’Neil P., McKay J., Melvin W.T., FothergillJ.E.: Matrix metalloproteinase‑1 is associated with poor prognosisin oesophageal cancer. J. Pathol., 1998; 185: 256‑261
  Google Scholar
• 40. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M.: Matrixmetalloproteinases: biologic activity and clinical implications.J. Clin. Oncol., 2000; 18: 1135‑1149
  Google Scholar
• 41. Nissinen L., Kähäri V.M.: Matrix metalloproteinases in inflammation.Biochim. Biophys. Acta, 2014; 1840: 2571‑2580
  Google Scholar
• 42. Nowak K., Szyfter W.: Nowotwory krtani. W: Szyfter W., red. Nowotworyw Otolarynglogii. Poznań: Termedia, 2012: 275‑329
  Google Scholar
• 43. O‑charoenrat P., Rhys‑Evans P.H., Eccles S.A.: Expression of matrixmetalloproteinases and their inhibitors correlates with invasionand metastasis in squamous cell carcinoma of the head and neck.Arch. Otolaryngol. Head Neck Surg., 2001; 127: 813‑820
  Google Scholar
• 44. Osuch‑Wójcikiewicz E.: Rak krtani i gardła dolnego. W: JanczewskiG. (red.), Otorynolaryngologia Praktyczna. Via Medica; Gdańsk:2007: 507‑517
  Google Scholar
• 45. Papadas T.A., Naxakis S.S., Mastronikolis N.S., Stathas T,. KarabekosN.C., Tsiambas E.: Determination of matrix metalloproteinase 9(MMP‑9) protein expression in laryngeal squamous cell carcinomasbased on digital image analysis. J. BUON, 2013; 18: 977‑981
  Google Scholar
• 46. Peschos D., Damala C., Stefanou D., Tsanou E., AssimakopoulosD., Vougiouklakis T., Charalabopoulos K., Agnantis N.J.: Expression ofmatrix metalloproteinase‑9 (gelatinase B) in benign, premalignantand malignant laryngeal lesions. Histol. Histopathol., 2006; 21: 603‑608
  Google Scholar
• 47. Rosenthal E.L., Matrisian L.M.: Matrix metalloproteases in headand neck cancers. Head Neck, 2006; 28: 639‑648
  Google Scholar
• 48. Samantaray S., Sharma R., Chattopadhyaya T.K., Datta Gupta S.,Ralhan R.: Increased expression of MMP‑2 and MMP‑9 in esophagealsquamous cell carcinoma. J. Cancer Res. Clin. Oncol., 2004; 130: 37‑44
  Google Scholar
• 49. Shields S.E., Ogilvie D.J., McKinnell R.G., Tarin D.: Degradationof basement membrane collagens by metalloproteases released byhuman, murine and amphibian tumours. J. Pathol., 1984; 143: 193‑197
  Google Scholar
• 50. Stocker W., Grams F., Baumann U., Reinemer P., Gomis‑Ruth F.X.,McKay D.B., Bode W.: The metzincins – topological and sequential relationsbetween the astacins, adamalysins and matrixins (collagenases)define a superfamily of zinc‑peptidases. Protein Sci., 1995; 4: 823‑840
  Google Scholar
• 51. Suarez‑Alvarez B., Garcia Suarez M.M., Argüelles M.E., SampedroA., Alvarez Marcos C., Mira E., Van den Brul F.A., Liu F.T., ChowdhuryP.S., de los Toyos J.R.: Circulating IgG response to stromelysin‑3,collagenase‑3, galectin‑3 and mesothelin in patients with pharynx/larynx squamous cell carcinoma. Anticancer Res., 2001; 21: 3677‑3684
  Google Scholar
• 52. Śliwowska I., Kopczyński Z.: Metaloproteinazy macierzy zewną-trzkomórkowej‑charakterystyka biochemiczna i kliniczna wartośćoznaczania u chorych na raka piersi. Współ. Onkol., 2005; 9: 327‑335
  Google Scholar
• 53. Talamini R., Bosetti C., La Vecchia C., Dal Maso L., Levi F., Bidoli E.,Negri E., Pasche C., Vaccarella S., Barzan L., Franceschi S.: Combinedeffect of tobacco and alcohol on laryngeal cancer risk: a case‑controlstudy. Cancer Causes Control., 2002; 13: 957‑964
  Google Scholar
• 54. Tang X., Shen X., Qian X., Gao X.: Expressions of HMGB1, MMP‑2and MMP‑9 and prognostic alue in human laryngeal carcinoma.Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2013; 27: 181‑187
  Google Scholar
• 55. Visse R., Nagase H.: Matrix metalloproteinases and tissue inhibitorsof matrix metalloproteinases: structure, function, and biochemistry.Circ. Res., 2003; 92: 827‑839
  Google Scholar
• 56. Vu T.H., Werb Z.: Matrix metalloproteinases: effectors of developmentand normal physiology. Genes Dev., 2000; 14: 2123‑2133
  Google Scholar
• 57. Wittekindt C., Jovanovic N., Guntinas‑Lichius O.: Expressionof matrix metalloproteinase‑9 (MMP‑9) and blood vessel densityin laryngeal squamous cell carcinomas. Acta Otolaryngol., 2011;131: 101‑106
  Google Scholar
• 58. Xie M., Sun Y., Li Y.: Expression of matrix metalloproteinasesin supraglottic carcinoma and its clinical implication for estimatinglymph node metastases. Laryngoscope, 2004; 114: 2243‑2248
  Google Scholar
• 59. Yana I., Seiki M.: MT‑MMPs play pivotal roles in cancer dissemination.Clin. Exp. Metastasis, 2002; 19: 209‑215
  Google Scholar
• 60. Yüce I., Bayram A., Cağlı S., Canöz O., Bayram S., Güney E.: Therole of CD44 and matrix metalloproteinase–9 expression in predictingneck metastasis of supraglottic laryngeal carcinoma. Am. J.Otolaryngol., 2011; 32: 141‑146
  Google Scholar
• 61. Zhang H., Liu M., Sun Y., Lu J.: MMP‑14 can serve as a prognosticmarker in patients with supraglottic cancer. Eur. Arch. Otorhinolaryngol.,2009; 266: 1427‑1434
  Google Scholar

Full text